Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Apellis Pharmaceuticals Inc (APLS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 755,906
  • Shares Outstanding, K 56,243
  • Annual Sales, $ 0 K
  • Annual Income, $ -51,010 K
  • 36-Month Beta 0.26
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 4.22

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate -0.65
  • Number of Estimates 1
  • High Estimate -0.65
  • Low Estimate -0.65
  • Prior Year -0.60
  • Growth Rate Est. (year over year) -8.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
12.16 +5.35%
on 12/27/18
15.39 -16.76%
on 01/16/19
-1.47 (-10.29%)
since 12/21/18
3-Month
11.45 +11.88%
on 10/24/18
20.53 -37.62%
on 12/04/18
-0.48 (-3.61%)
since 10/23/18
52-Week
11.45 +11.88%
on 10/24/18
32.00 -59.97%
on 04/16/18
-5.12 (-28.56%)
since 01/23/18

Most Recent Stories

More News
Apellis Pharmaceuticals (APLS) in Focus: Stock Moves 7.1% Higher

Apellis Pharmaceuticals (APLS) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

APLS : 12.81 (-4.69%)
ACOR : 16.01 (+0.50%)
Apellis Pharmaceuticals to Present at the 37th Annual J.P. Morgan Healthcare Conference

Apellis Pharmaceuticals Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement...

JPM : 102.68 (-0.25%)
APLS : 12.81 (-4.69%)
Apellis Pharmaceuticals' APL-2 Receives Orphan Drug Designation from the FDA for the Treatment of C3 Glomerulopathy

Apellis Pharmaceuticals Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat diseases through inhibition of the complement system,...

APLS : 12.81 (-4.69%)
Apellis Pharmaceuticals Provides Update on Its Phase 3 Program for Patients with Geographic Atrophy

Phase 3 geographic atrophy program enrollment timeline currently unchanged; program enrollment is expected to restart in Q2 2019 and enrollment completion is expected in Q1 2020

APLS : 12.81 (-4.69%)
ARA to Demo New Simulation Technologies at I/ITSEC 2018

Applied Research Associates, Inc. (ARA) will demo their latest cutting-edge simulation software at the 2018 Interservice/Industry Training, Simulation and Education Conference (I/ITSEC). Conference-goers...

APLS : 12.81 (-4.69%)
Apellis Pharmaceuticals Expands Leadership Team, Appoints Adam Townsend as Chief Commercial Officer

Apellis Pharmaceuticals, Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement...

APLS : 12.81 (-4.69%)
Market Trends Toward New Normal in Fibrocell Science, Sears Hometown and Outlet Stores, Apellis Pharmaceuticals, Sigma Labs, Highpower International, and Nicholas Financial -- Emerging Consolidated Expectations, Analyst Ratings

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Fibrocell Science Inc (NASDAQ:FCSC),...

HPJ : 2.87 (unch)
NICK : 10.80 (+0.14%)
APLS : 12.81 (-4.69%)
SGLB : 2.09 (-0.48%)
FCSC : 1.89 (-3.08%)
SHOS : 2.15 (+4.88%)
Apellis Pharmaceuticals Reports Third Quarter 2018 Business Update and Financial Results

- Commenced Phase 3 Program of APL-2 in Geographic Atrophy (GA) -

APLS : 12.81 (-4.69%)
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences

Apellis Pharmaceuticals Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement...

APLS : 12.81 (-4.69%)
Intrexon Announces the Formation of Bioinformatics Hub in Munich

Intrexon Corporation (NASDAQ: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, today announced the formation of Intrexon Bioinformatics...

XON : 7.76 (-3.48%)
APLS : 12.81 (-4.69%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More Share

Trade APLS with:

Business Summary

Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the...

See More

Key Turning Points

2nd Resistance Point 13.72
1st Resistance Point 13.27
Last Price 12.81
1st Support Level 12.46
2nd Support Level 12.10

See More

52-Week High 32.00
Fibonacci 61.8% 24.15
Fibonacci 50% 21.73
Fibonacci 38.2% 19.30
Last Price 12.81
52-Week Low 11.45

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar